Disagree
Home Dragon Pharma Dragon Pharma
MK 2866
MK 2866 - Dragon Pharma

MK 2866 - Dragon Pharma

Brand:
Category:
Substance:
Dosage:
25 mg/tab
Package:
100 tablets
Price:
$90.00 - $140.00
See options
Product Overview
Ostarine, also known as Enobosarm (MK-2866), is a non-steroidal SARM that selectively targets androgen receptors in muscle and bone tissue. Unlike anabolic steroids, it promotes muscle growth without significant androgenic effects in other tissues such as the prostate. Initially developed to combat muscle wasting and osteoporosis, it gained popularity in the fitness community for its ability to increase lean body mass and improve strength. Despite its anabolic effects, Ostarine exhibits minimal side effects compared to traditional steroids, making it a preferred option for cutting and recomp cycles .
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about MK 2866 by Dragon Pharma, consult with your doctor or healthcare professional.

Products
Show more
Explore More Products
FAQ
What is Ostarine?
Ostarine is a non-steroidal selective androgen receptor modulator (SARM) that selectively activates androgen receptors in muscle and bone for anabolic effects .
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

How does Ostarine work?
Ostarine binds the androgen receptor in skeletal muscle, supporting protein synthesis and satellite-cell activation with minimal prostate or skin effects .
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

Is Ostarine approved for human use?
No. Ostarine remains an investigational “research compound” and is not approved as a prescription drug .
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.